Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

OMER


Top 10 Correlated ETFs

OMER


Top 10 Correlated Stocks

OMER


In the News

08:33 13 Aug 2022 OMER

Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript

Omeros Corporation. (NASDAQ:OMER ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Chief Commercial Officer Conference Call Participants Greg Harrison - Bank of America Steve Brozak - WBB Hannah Adeoye - JPMorgan Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.

02:48 13 Aug 2022 OMER

Why Omeros Corporation Stock Is Marching Higher Today

A positive regulatory development is powering the biotech's shares higher today.

05:46 13 Aug 2022 OMER

Why Omeros Stock Is Freefalling Today

It's reverting to where it was before its massive uptick last week.

12:47 13 Aug 2022 OMER

Omeros: On Death's Door

Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty.

10:26 13 Aug 2022 OMER

Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Eric Joseph - JPMorgan Greg Harrison - Bank of America Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.

10:18 13 Aug 2022 OMER

Omeros: The Weight Of The Wait, A Conundrum

Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.

08:01 13 Aug 2022 OMER

Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript

Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript

09:59 13 Aug 2022 OMER

Why Earnings Season Could Be Great for Omeros (OMER)

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

07:49 13 Aug 2022 OMER

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting.

06:54 13 Aug 2022 OMER

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).  The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.

Financial details

Company Rating
Neutral
Market Cap
456.77M
Income
196.31M
Revenue
-21.06M
Book val./share
-0.08
Cash/share
2.27
Dividend
-
Dividend %
-
Employees
213
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
2.27
Forward P/E
-
PEG
-0.1
P/S
-21.23
P/B
-90.81
P/C
3.14
P/FCF
-5.27
Quick Ratio
5.78
Current Ratio
6
Debt / Equity
-68.67
LT Debt / Equity
-68.67
-
-
EPS (TTM)
3.13
EPS next Y
-
EPS next Q
-0.63
EPS this Y
-229.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-111.83%
-
-
-
-
SMA20
58.31%
SMA50
146.33%
SMA100
3.91%
Inst Own
47.6%
Inst Trans
-2.99%
ROA
53%
ROE
-160%
ROC
-0.53%
Gross Margin
99%
Oper. Margin
845%
Profit Margin
-932%
Payout
-
Shs Outstand
62.73M
Shs Float
60.2M
-
-
-
-
Target Price
-
52W Range
1.86-16.57
52W High
-55.44%
52W Low
+613%
RSI
69.53
Rel Volume
0.42
Avg Volume
1.52M
Volume
643.92K
Perf Week
32.53%
Perf Month
159.27%
Perf Quarter
0.56%
Perf Half Y
5.63%
-
-
-
-
Beta
0.7169
-
-
Volatility
0.56%, 1.21%
Prev Close
-0.97%
Price
7.13
Change
-3.52%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
1.420.612.261.290
Net income per share
-1.17-2.61-1.71-2.413.12
Operating cash flow per share
-0.8-2.14-1.21-1.75-1.76
Free cash flow per share
-0.8-2.15-1.22-1.76-1.76
Cash per share
1.841.251.232.362.52
Book value per share
-0.06-2.06-2.2-2.110.38
Tangible book value per share
-0.06-2.06-2.2-2.110.38
Share holders equity per share
-0.06-2.06-2.2-2.110.38
Interest debt per share
2.073.43.654.65.89
Market cap
755.04M635.95M646.78M1.11B351M
Enterprise value
834.96M779.07M801.91M1.34B598.03M
P/E ratio
-14.12-5.02-7.66-8.061.81
Price to sales ratio
11.6521.295.7815.070
POCF ratio
-20.84-6.13-10.77-11.12-3.2
PFCF ratio
-20.64-6.1-10.71-11.09-3.19
P/B Ratio
-268.32-6.35-5.93-9.2114.76
PTB ratio
-268.32-6.35-5.93-9.2114.76
EV to sales
12.8826.087.1718.130
Enterprise value over EBITDA
-19.93-6.36-13.36-11-3.51
EV to operating cash flow
-23.05-7.51-13.35-13.37-5.45
EV to free cash flow
-22.83-7.47-13.28-13.34-5.44
Earnings yield
-0.07-0.2-0.13-0.120.55
Free cash flow yield
-0.05-0.16-0.09-0.09-0.31
Debt to equity
-29.6-1.49-1.45-1.9614.41
Debt to assets
1.022.041.81.670.94
Net debt to EBITDA
-1.91-1.17-2.58-1.86-1.45
Current ratio
4.122.411.874.124.79
Interest coverage
-3.98-6.91-2.8-4.13-8.83
Income quality
0.680.820.710.72-0.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.81.730.580.980
Research and developement to revenue
0.863.010.981.50
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.0100
Capex to revenue
-0.01-0.02000
Capex to depreciation
-0.64-0.59-0.19-0.18-0.2
Stock based compensation to revenue
0.20.390.120.20
Graham number
1.28119.1910.715.17
ROIC
-0.49-1.92-0.78-0.77-0.47
Return on tangible assets
-0.46-1.32-0.62-0.760.46
Graham Net
-0.49-2.44-3.2-2.86-2.83
Working capital
82.07M52.51M48.29M114.55M196.1M
Tangible asset value
00000
Net current asset value
-10.77M-106.23M-142.25M-150.51M-147.6M
Invested capital
-29.6-1.49-1.45-1.9614.63
Average receivables
10.49M13.33M19.51M3.84M43.16M
Average payables
5.45M5.24M4.76M4.2M8.8M
Average inventory
899K721.5K1.25M1.36M0
Days sales outstanding
96.53278.85114.8718.990
Days payables outstanding
2.27K4.48K2.25K1.7K0
Days of inventory on hand
15062.73483.99548.310
Receivables turnover
3.781.313.1819.220
Payables turnover
0.160.080.160.210
Inventory turnover
2.435.820.750.670
ROE
19.011.270.771.148.17
Capex per share
-0.01-0.01-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.340.460.48-1.280
Net income per share
-0.57-0.46-0.364.49-0.53
Operating cash flow per share
-0.65-0.44-0.38-0.29-0.24
Free cash flow per share
-0.65-0.44-0.38-0.29-0.24
Cash per share
1.621.180.812.512.27
Book value per share
-3.58-3.95-4.20.38-0.08
Tangible book value per share
-3.58-3.95-4.20.38-0.08
Share holders equity per share
-3.58-3.95-4.20.38-0.08
Interest debt per share
5.635.675.655.645.53
Market cap
1.1B925.62M862.02M402.21M376.98M
Enterprise value
1.44B1.26B1.2B649.24M710.14M
P/E ratio
-7.85-8.09-9.490.36-2.85
Price to sales ratio
52.3432.1128.73-5.030
POCF ratio
-27.38-33.55-36.43-22.08-24.81
PFCF ratio
-27.38-33.44-36.27-21.99-24.81
P/B Ratio
-4.97-3.76-3.2816.91-76.54
PTB ratio
-4.97-3.76-3.2816.91-76.54
EV to sales
68.2343.7840.09-8.130
Enterprise value over EBITDA
-48.22-54.09-68.842.27-20.72
EV to operating cash flow
-35.7-45.73-50.84-35.64-46.74
EV to free cash flow
-35.69-45.58-50.62-35.5-46.74
Earnings yield
-0.03-0.03-0.030.7-0.09
Free cash flow yield
-0.04-0.03-0.03-0.05-0.04
Debt to equity
-1.53-1.4-1.3114.41-68.67
Debt to assets
2.372.693.130.941.01
Net debt to EBITDA
-11.23-14.41-19.510.86-9.72
Current ratio
3.052.362.134.796
Interest coverage
-6.25-4.89-3.72-20.35-7.09
Income quality
1.150.961.04-0.060.46
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.860.750.70.070
Research and developement to revenue
1.581.070.9-0.340
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.03-0.25-0.32-0.230
Stock based compensation to revenue
0.160.110.19-0.070
Graham number
6.766.385.866.190.96
ROIC
-0.26-0.25-0.23-0.27-0.1
Return on tangible assets
-0.22-0.2-0.180.67-0.09
Graham Net
-4.26-4.71-4.96-2.82-2.98
Working capital
89.05M64.7M48.53M196.1M175.16M
Tangible asset value
00000
Net current asset value
-250.92M-279.29M-294.78M-147.6M-163.97M
Invested capital
-1.55-1.42-1.3314.63-69.47
Average receivables
53.65M57.16M58.19M82.47M71.42M
Average payables
12.45M11.45M11.71M13.4M10.37M
Average inventory
00000
Days sales outstanding
106.0999.41101.68-92.910
Days payables outstanding
3.94K2.5K2.71K-1.29K0
Days of inventory on hand
407.57257.37192.4300
Receivables turnover
0.850.910.89-0.970
Payables turnover
0.020.040.03-0.070
Inventory turnover
0.220.350.4700
ROE
0.160.120.0911.86.7
Capex per share
00000

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap